Patents by Inventor Yahu LIU

Yahu LIU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY
    Publication number: 20230348852
    Abstract: The present invention provides ocular cells, genetically modified by a CRISPR system targeting the expression of B2M for ocular cell therapy. The invention further provides methods of generating an expanded population of genetically modified ocular cells, for example limbal stem cells (LSCs) or corneal endothelial cells (CECs), wherein the cells are expanded involving the use of a LATS inhibitor and the expression of B2M in the cells has been reduced or eliminated. The present invention also provides cell populations, preparations, uses and methods of therapy comprising said cells.
    Type: Application
    Filed: April 26, 2021
    Publication date: November 2, 2023
    Inventors: Frada BERENSHTEYN, Bo HAN, Xueshi HAO, Jessica HEYDER, Timothy Z. HOFFMAN, Qihui JIN, Arnaud LACOSTE, Jun LIU, Yahu LIU, Tingting MO, Bradley Andrew MURRAY, Daniel Joseph O’CONNELL, Jianfeng PAN, Yun Feng XIE, Shanshan YAN, Yefen ZOU
  • 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors
    Publication number: 20230190751
    Abstract: The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined herein. The present invention further relates to a method of LATS inhibition in a cell population using a compound of Formula A1, or a salt, stereoisomer or pharmaceutical composition thereof. The present invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, their use in the treatment and management of diseases or disorders.
    Type: Application
    Filed: August 18, 2022
    Publication date: June 22, 2023
    Inventors: Dirk BEHNKE, Frada BERENSHTEYN, Xueshi HAO, Timothy Z. HOFFMAN, Qihui JIN, Arnaud LACOSTE, Cameron LEE, Jun LIU, Yahu A. LIU, Juergen Klaus MAIBAUM, Tingting MO, Jianfeng PAN, Xin QU, Jan TCHORZ, Yun Feng XIE, Shanshan YAN, Yefen ZOU
  • 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors
    Patent number: 11458138
    Abstract: The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined herein. The present invention further relates to a method of LATS inhibition in a cell population using a compound of Formula A1, or a salt, stereoisomer or pharmaceutical composition thereof. The present invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, their use in the treatment and management of diseases or disorders.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: October 4, 2022
    Assignee: Novartis AG
    Inventors: Dirk Behnke, Frada Berenshteyn, Xueshi Hao, Timothy Hoffman, Qihui Jin, Arnaud Lacoste, Cameron Lee, Jun Liu, Yahu Liu, Juergen Klaus Maibaum, Tingting Mo, Jianfeng Pan, Xin Qu, Jan Tchorz, Yun Feng Xie, Shanshan Yan, Yefen Zou
  • METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY
    Publication number: 20200131474
    Abstract: The present invention provides ocular cells, genetically modified by a CRISPR system targeting the expression of B2M for ocular cell therapy. The invention further provides methods of generating an expanded population of genetically modified ocular cells, for example limbal stem cells (LSCs) or corneal endothelial cells (CECs), wherein the cells are expanded involving the use of a LATS inhibitor and the expression of B2M in the cells has been reduced or eliminated. The present invention also provides a cell populations, preparations, uses and methods of therapy comprising said cells.
    Type: Application
    Filed: October 25, 2019
    Publication date: April 30, 2020
    Inventors: Frada BERENSHTEYN, Bo HAN, Xueshi HAO, Jessica HEYDER, Timothy Z. HOFFMAN, Qihui JIN, Arnaud LACOSTE, Jun LIU, Yahu LIU, Tingting MO, Bradley Andrew MURRAY, Daniel Joseph O'CONNELL, Jianfeng PAN, Yun Feng XIE, Shanshan YAN, Yefen ZOU
  • 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors
    Publication number: 20180344738
    Abstract: The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined herein. The present invention further relates to a method of LATS inhibition in a cell population using a compound of Formula A1, or a salt, stereoisomer or pharmaceutical composition thereof. The present invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, their use in the treatment and management of diseases or disorders.
    Type: Application
    Filed: April 26, 2018
    Publication date: December 6, 2018
    Inventors: Dirk BEHNKE, Frada BERENSHTEYN, Xueshi HAO, Timothy HOFFMAN, Qihui JIN, Arnaud LACOSTE, Cameron LEE, Jun LIU, Yahu LIU, Juergen Klaus MAIBAUM, Tingting MO, Jianfeng PAN, Xin QU, Jan TCHORZ, Yun Feng XIE, Shanshan YAN, Yefen ZOU